Umoja Biopharma | $100,000,000 | (Jan 21, 2025)
Fundment | $55,157,175 | (Jan 21, 2025)
r4 | $1,000,000 | (Jan 21, 2025)
Certified by Founder
Lodge
Shinobi Therapeutics
start up
United States
- South San Francisco, CA
- 13/12/2023
- Series A
- $51,000,000
Shinobi Therapeutics is developing a new class of hypoimmune CD8ab iPS-T cells for cancer and beyond by using immune evasion to unlock the full potential of iPSCs.
- Industry Biotechnology Research
- Website https://www.shinobitx.com/
- LinkedIn https://www.linkedin.com/company/shinobitx/about/
Related People
Dan KempFounder
United States -
New York City Metropolitan Area
Accomplished BioPharma Executive with experience in drug discovery (Novartis), translational and clinical development (Merck), sell-side, buy-side and M&A transactional BD (Takeda), Executive oversight (GammaDelta Therapeutics, Adaptate Therapeutics) and Operational Leadership (Cell Therapies at Takeda).
IntusCare | $11,500,000 | (Jan 21, 2025)
Alteva Technologies | $1,760,526 | (Jan 21, 2025)
ecoplanet | $16,571,680 | (Jan 21, 2025)
StepChange.work | $4,000,000 | (Jan 21, 2025)
Sereact | $25,894,660 | (Jan 21, 2025)
Men In Blazers Media Network | $150,000,000 | (Jan 21, 2025)
Pipe17 | $15,500,000 | (Jan 17, 2025)
Coram AI | $13,800,000 | (Jan 17, 2025)
Quantifind | $22,000,000 | (Jan 17, 2025)